MSLE Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 2.33%, SMA50 30.53%, SMA200 79.39%). The stock’s 14-day RSI is 63.49 (firm momentum), while the ATR of 0.71 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.72% below its high and over 157.46% above its low. Average 10-day trading volume of 81.26 thousand shares is below the 3-month average of 98.76 thousand, indicating normal recent market interest.

Satellos Bioscience Inc. Common Stock generated EPS of -$1.57 over the past year. Five-year average earnings growth is 5.62%. Wall Street analysts project EPS growth of 6.14% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $11.00. The high target offers 155.43% upside. The low target suggests 40.49% downside. The mean target is $15.50. This offers 97.96% upside. Satellos Bioscience Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 11.14%.

Satellos Bioscience Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.20. This means the shares are trading above this model’s fair value.

Satellos Bioscience Inc. Common Stock (NASDAQ:MSLE) closed at $7.83 USD, losing -$0.87 (-10.00%) from the previous close of $8.70. The stock is currently mid-range between its 52-week high and low $4.52 and $13.39. With a market capitalization of about $10.09 million, Satellos Bioscience Inc. Common Stock is classified as a micro-cap and shows market-like volatility (beta ~1.08). Key stats such as the average daily volume over the past year has been around 81.70 thousand shares, volume is running light vs its 52-week average. Headquartered in Toronto, ON, Satellos Bioscience Inc. Common Stock operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Francis Gleeson, the company employs approximately 14 people and listed since May 10, 2024. Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics.

Our AI price prediction model suggests that Satellos Bioscience Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -18.65%, with price expected at $6.37 by May 04, 2026, within a range of $4.69 to $8.04 3-Month Outlook: Projected fall of -51.34%, reaching $3.81 by July 16, 2026, with a range of $3.71 to $3.91. 1-Year Outlook: Projected loss of -90.55%, with price at $0.74 by April 20, 2027, within a range of $0.63 to $0.82.

currently trading near 52-week highs band. Valuation shows Satellos Bioscience Inc. Common Stock trading at a premium to the broader market with a P/E of -5.25. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $15.50, suggesting 97.96% upside. Our AI forecast model points to short-term weakness (-18.65% over two weeks), a medium-term fall (-51.34% over three months), and a longer-term loss (-90.55% over one year), with expected trading ranges indicating moderate volatility.

Satellos Bioscience Inc. Common Stock trades at a P/E ratio of -5.25, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.22 trading at moderately above to book value. The P/FCF stands at -0.48, also below market averages.